A look at CP's coverage plans for back to school 2025
Stories and approximate run dates:
Harvard-Canadians: The Trump administration's decision to bar international students from Harvard earlier this year left Canadian students who had hopes for completing their Ivy League education at the Massachusetts school anxious about their futures. We check back in with them as the school year approaches. By Cassidy McMackon. Moves Aug 15.
Measles-Vaccine-Schedule: Some provinces give the second dose of the measles vaccine at 18 months, while others don't give the second dose until age four. This means that some kids in Ontario, for instance, might be entering school without being fully protected amid the province's outbreak that has sickened more than 2,000 people. Here's what the experts say parents should know about the different schedule, and why they should consider fully vaccinating their toddlers before September. By Hannah Alberga. Aug. 18.
Cda-Universities-AI: A look at how Canadian universities are navigating the use of artificial intelligence by students and teachers — and how schools are trying to ensure the technology improves learning outcomes rather than worsening them. Maan Alhmidi. Aug. 19
Teaching-Influencing: Gen Z increasingly sees influencer marketing as a viable career choice and several Canadian school are pitching courses teaching them to become just that— what skills to they teach, and how popular are they? By Nicole Thompson. Moves Aug. 21.
Teaching-Climate-Change: Teachers share how they use major weather events to help explain the impact of climate change to children, but face restrictions with the current curriculum. By Cassidy McMackon. Moves: Aug. 22
Student-Woes-Vignettes: The challenges facing post-secondary students have been amplified by a cost-of-living crisis, fractured political climate and increasing social isolation driven in part by AI and smartphone technology. We speak to some of them about their lives. By Rianna Lim. Aug. 24
Young-Influencers: A look at how some young influencers plan to navigate their studies with their plans to continue posting about their lives online — especially those whose profiles blew up over the summer. By Vanessa Tibeiro. Moves Aug. 25.
Financial-Literacy: Recent data shows Gen Z is better at saving than Millennials, with many saying they learn about finances online. A look at how even those who are minors are taught about money, and what's behind the increased awareness as young people prepare to enter into a cost-of-living crisis. By Natasha Baldin. Aug. 26
School-Lunches: Many parents who aren't Meghan Markle dread planning school lunches. How to master package-less, nut-free, whole-food meals to satiate picky eaters in a rush. By Cassandra Szklarski. Aug. 27
Medical-School-Students: We talk to first-year medical students who are the first in their family to pursue a career as a doctor and have faced racial, economic or social barriers to get there. By Nicole Ireland. Aug. 30
Bullying-Prep: Tips on how Black, racialized and neurodiverse youth can navigate social and school situations safely. By Cassandra Szklarski/Nicole Thompson. Sept. 2
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Market Online
4 hours ago
- The Market Online
U.S. federal cannabis rescheduling: A game-changer for Canopy Growth?
The U.S. government is considering reclassifying cannabis from Schedule I to Schedule III, which would recognize its medical benefits, ease research restrictions, and offer tax relief to cannabis businesses Through its Canopy USA structure, Canopy Growth holds stakes in major U.S. cannabis companies like Acreage Holdings, Wana Brands, and Jetty, positioning itself to capitalize on federal policy changes Canopy Growth reported a 43 per cent year-over-year increase in Canadian adult-use cannabis revenue in Q1 FY2026, signaling operational momentum as it prepares for potential U.S. market expansion Canopy Growth stock (TSX:WEED) last traded at C$2.08 The United States could be on the cusp of a transformative shift in federal cannabis policy. Recent statements from President Donald Trump and widespread media coverage confirm that the administration is currently reviewing a proposal to reclassify cannabis from a Schedule I to a Schedule III controlled substance. This content has been prepared as part of a partnership with Canopy Growth Corp. and is intended for informational purposes only. This reclassification would mark the most significant federal policy change in over 50 years, formally acknowledging cannabis's medical utility and opening new avenues for research, patient access, and industry growth. Currently, cannabis is classified alongside heroin and LSD under Schedule I, a category reserved for substances with no accepted medical use and high abuse potential. Moving it to Schedule III—alongside drugs like ketamine and anabolic steroids—would signal a federal recognition of its therapeutic potential and reduce regulatory burdens. Implications of Schedule III reclassification If cannabis is reclassified, the following changes are expected: Medical recognition : Cannabis would be federally acknowledged as having medical benefits, aligning U.S. policy more closely with countries like Canada, Germany, and Australia. : Cannabis would be federally acknowledged as having medical benefits, aligning U.S. policy more closely with countries like Canada, Germany, and Australia. Expanded research : Researchers would gain broader access to cannabis products for clinical trials, overcoming the restrictive barriers imposed by Schedule I classification. : Researchers would gain broader access to cannabis products for clinical trials, overcoming the restrictive barriers imposed by Schedule I classification. Tax relief: Cannabis businesses would no longer be subject to Section 280E of the IRS tax code, which currently prevents them from deducting ordinary business expenses. This could significantly improve profitability across the sector. Regulatory clarity: While not full legalization, Schedule III status would provide a more stable regulatory environment, encouraging institutional investment and broader market participation. With the U.S. retail cannabis market projected to reach approximately US$50 billion by 2026, the stakes are … high. Canopy Growth: Positioned for U.S. expansion Canopy Growth Corp. (TSX:WEED, NASDAQ:CGC) has positioned itself to capitalize on the evolving U.S. cannabis landscape through its Canopy USA structure. This unconsolidated, non-controlling entity holds a portfolio of U.S. cannabis assets, including: Acreage Holdings, Inc. – A vertically integrated multi-state operator with a strong presence in the Northeast and Midwest. – A vertically integrated multi-state operator with a strong presence in the Northeast and Midwest. Wana Brands – An edibles company. – An edibles company. Jetty (Lemurian, Inc.) – A California-based producer of premium cannabis extracts and vape technology. – A California-based producer of premium cannabis extracts and vape technology. The Cima Group and Wana Wellness – Expanding Canopy's reach into wellness and lifestyle segments. This structure allows Canopy to maintain compliance with U.S. federal regulations while retaining exposure to the upside of U.S. market growth. Shareholders recently approved the creation of a new class of exchangeable shares; a move designed to accelerate Canopy's U.S. market entry and enhance flexibility. Financial momentum and solid readiness Canopy Growth's Q1 FY2026 results reflect a company regaining momentum: Canada adult-use cannabis net revenue rose 43 per cent year-over-year to C$27 million , driven by strong demand for new products like Claybourne infused pre-rolls. rose to , driven by strong demand for new products like Claybourne infused pre-rolls. Total cannabis revenue increased 24% , while consolidated net revenue grew 9 per cent to C$72.1 million . increased , while consolidated net revenue grew to . The company achieved CA$17 million of its CA$20 million annualized cost savings target and reduced SG&A expenses by 21 per cent. CEO Luc Mongeau emphasized the company's focus on high-demand product categories and retail distribution, while interim CFO Tom Stewart highlighted ongoing efforts to improve gross margins and operational efficiency, stating, 'Our financial discipline has already delivered meaningful operating expense reductions, and we see further opportunity to simplify and focus the business. Improving gross margin remains a key priority while maintaining topline performance in all areas of the business.' Investor takeaway: A catalyst for revaluation The potential rescheduling of cannabis to Schedule III could be a major catalyst for Canopy Growth and the broader cannabis sector. For Canopy, it would: Unlock tax savings and improve cash flow. Enable deeper integration of its U.S. assets under Canopy USA. Attract institutional investors previously deterred by regulatory uncertainty. Accelerate revenue growth in the world's largest cannabis market. While regulatory timelines remain uncertain, the momentum is clearly building. For investors, Canopy Growth represents a well positioned, financially disciplined player ready to seize the opportunities of a rescheduled U.S. cannabis market. About Canopy Growth Canopy Growth Corp. delivers products with a focus on premium and mainstream cannabis brands, in addition to vaporizer technology made in Germany. Canopy Growth stock (TSX:WEED) last traded around 8 per cent lower at C$2.08 on the TSX. Though it has risen 10 per cent since June, it has lost 47 per cent since the year began and 78 per cent since this time last year. On the NASDAQ, CGC stock also finished 8 per cent lower at US$1.50. It has risen more than 12 per cent since June but has lost 45 per cent since the year began and is 78 per cent lower since this time last year. Join the discussion: Find out what the Bullboards are saying about Canopy Growth and check out Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here .
Ottawa Citizen
7 hours ago
- Ottawa Citizen
Heat-related deaths and illnesses are on the rise in Canada
Heat-related deaths and illnesses are on the rise across Canada and expected to get worse in coming years, new research from Health Canada is warning. Article content Heat-related deaths, in particular, have increased rapidly in the past decade compared to the three decades preceding it, according to the analysis from the Climate Change and Health office at Health Canada. Two-thirds of heat-related deaths in Canada since 1981 occurred in just the last seven years. That period includes the years 2018 and 2021, when extreme heat events were responsible for hundreds of deaths, particularly in British Columbia, where at least 619 people died during an unprecedented heat dome in 2021. Temperatures soared above 40 degrees in many parts of the province. Article content Article content Article content The analysis comes during another hot summer in which there have been extended periods of extreme heat in many parts of Canada, including the most recent heat wave that has put Ottawa and much of eastern Canada under heat warnings for days. Article content Article content We can expect more of those and, with them, more deaths and severe health outcomes, the researchers warn. Article content 'Canada is experiencing warming at twice the rate of the global average due to climate change. The intensity and frequency of heat events in Canada are projected to increase in the future also because of climate change.' Article content Heat-related deaths in Canada are anticipated to increase by as much as 10.7 per cent by 2090, according to one projection. Article content Heat is already taking a serious toll on the health of Canadians, especially on the elderly, although heat-related deaths and illnesses may be underreported because data is inconsistent, limited and often incomplete. Article content Article content According to data from many, but not all provinces and territories, there were 916 recorded deaths caused by exposure to extreme heat in Canada between 1981 and 2022. Two-thirds, or 607, of those deaths occurred between 2016 and 2022, 328 of them in 2021 alone. Death rates for men were higher than for women, and more than 85 per cent of all heat-related deaths were in people over 45 years old, 30 per cent of them in people over 80. Article content Article content Those numbers are likely underreported, the paper notes, because it can be difficult to determine whether extreme heat 'was a causal or a contributing factor to these deaths.' Article content Heat-related deaths can occur in people with underlying heart or other preexisting diseases but are usually attributed to the underlying medical condition. In cases where people are found dead, it can also be difficult to attribute the death to hyperthermia, or heat stress.
Cision Canada
16 hours ago
- Cision Canada
Young Mother's Battle with Arthritis Highlights Need for Timely Access to Modern Medications in BC
VANCOUVER, BC, /CNW/ - Eileen Davidson, a Burnaby mother and advocate, is calling on the BC government to modernize its approach to rheumatoid arthritis (RA) treatment by removing barriers that prevent patients from accessing the medications they truly need—barriers not found in many other provinces. Diagnosed with seropositive rheumatoid arthritis at just 29 years old, Eileen spent years searching for answers while coping with disabling pain, extreme fatigue, and the emotional toll of chronic illness. "By the time I was diagnosed, I was on the verge of being placed on long-term disability," Eileen recalls. "I had a toddler at home and every day was a struggle just to care for him." Forced to Wait While Suffering Like many RA patients in BC, Eileen's path to relief was slowed by a policy known as Step Therapy. Under Step Therapy, patients are required to try and 'fail' on older, less effective medications—sometimes for a year or more—before they can access modern treatments like biologics that offer the best chance for remission. "My doctor and I both knew these medications weren't likely to work for me, but we had no choice," Eileen says. "All that time, my disease kept progressing, and my hope for a normal life was slipping away." Eliminating these treatment delays remains a key priority for Arthritis Society Canada, the national organization leading advocacy, research, and support for the six million Canadians with arthritis. "There is no cure for arthritis. And because arthritis medications often require trial and error to find what works, speed of access is critical in preventing irreversible damage," says Trish Barbato, President and CEO of Arthritis Society Canada. "What works for one person may not work for another, and people often become resistant to treatment over time, making timely access to a range of medications even more essential." Eileen's story is far from unique. Arthritis is the leading cause of disability in North America, affecting people of all ages, and early access to the right treatment is critical. Yet in BC, restrictive policies leave many patients—especially younger adults—facing avoidable disability, work loss, and deteriorating health. A Personal and Systemic Cost The impact goes beyond the individual. Untreated or undertreated RA can lead to irreversible joint damage, increased healthcare use, and higher costs for the system as a whole. "If I'd had access to effective treatment earlier, I might still be working full-time," says Eileen. "Instead, I lost years to pain and fatigue, and my disease progressed much faster than it needed to." MedAccessBC Calls for Policy Change Eileen's experience underscores a larger, systemic issue that the Medicines Access Coalition – BC (MedAccessBC) has been fighting to address for over two decades. "Forcing patients to fail on older medications before approving access to newer, proven treatments is not only out of step with medical evidence—it's unfair and costly in the long run," says Jamie Myrah, Co-Chair of MedAccessBC. "All British Columbians deserve the opportunity for the best possible health outcomes, not arbitrary delays." As a non-profit coalition representing over 30 patient care organizations, MedAccessBC urges the BC government to review and update Step Therapy policies for rheumatoid arthritis and similar chronic conditions, ensuring that treatment decisions prioritize patient well-being and clinical best practices. A Call to Action Eileen's message to policymakers is clear: "Please give people like me a fighting chance to live, work, and participate fully in our communities. Timely access to the right medication isn't a luxury—it's a lifeline." About Rheumatoid Arthritis (RA) Rheumatoid arthritis is an autoimmune disease that causes the body's immune system to attack healthy joints and tissues. It can strike at any age and leads to pain, swelling, and fatigue. If not treated effectively and early, RA can result in severe disability, organ complications, and reduced life expectancy. There are more than 100 types of arthritis and related autoimmune conditions, affecting millions of Canadians. (Arthritis Society Canada) About the Medicines Access Coalition of BC MedAccess BC advocates for improved access to medications and health technologies for individuals with chronic diseases. Representing over 30 patient organizations, it has been working since 1997 to improve access to evidence-based medicines through BC's PharmaCare program. About Arthritis Society Canada Arthritis Society Canada represents the six million people in Canada living with arthritis today, and the millions more who are impacted or at risk. Fueled by the trust and support of our donors and volunteers, Arthritis Society Canada is fighting arthritis with research, advocacy, innovation, information and support. We are Canada's largest charitable funder of cutting-edge arthritis research. We will not give up our efforts until everyone is free from the agony of arthritis. Arthritis Society Canada is accredited under Imagine Canada's Standards Program. For more information, visit
